论文部分内容阅读
目的:探究甘氨双唑钠联合苦参注射液治疗食管癌术后复发患者的临床疗效和安全性。方法:选取经食管癌术后复发62例患者,随机分成对照组与联合组,每组31例。对照组给予甘氨双唑钠治疗,联合组在对照组基础上给予苦参注射液治疗。观察并比较两组患者治疗前后血清肿瘤标记物CEA、CA19-9、Cyfra21-1及SCC水平、1年和3年生存率、临床疗效及不良反应的发生情况。结果:与治疗前比较,两组患者治疗后血清CEA、CA19-9、Cyfra21-1及SCC水平均降低(P<0.05);且与对照组比较,联合组治疗后血清CEA、CA19-9、Cyfra21-1及SCC水平均较低(P<0.05),3年生存率较高(P<0.05),不良反应如恶心、呕吐、腹泻、肌酐升高、转氨酶升高及白细胞降低发生率更低(P<0.05)。结论:甘氨双唑钠联合苦参注射液可有效提高食管癌术后复发患者的临床疗效,延长患者生存时间,且安全性较高。
Objective: To investigate the clinical efficacy and safety of glycopyrrolate combined with matrine injection in the treatment of postoperative recurrence of esophageal cancer. Methods: Sixty-two patients with esophageal carcinoma who underwent esophagectomy were randomly divided into control group and combination group, with 31 cases in each group. The control group was treated with glycidodiazole sodium, and the combination group was given Kushen injection on the basis of the control group. The levels of serum tumor markers CEA, CA19-9, Cyfra21-1 and SCC, 1-year and 3-year survival rates, clinical efficacy and adverse reactions were observed and compared between the two groups before and after treatment. Results: Compared with those before treatment, the levels of CEA, CA19-9, Cyfra21-1 and SCC were decreased in both groups after treatment (P <0.05). Compared with the control group, serum CEA, CA19-9, Cyfra21-1 and SCC levels were lower (P <0.05), 3-year survival rate was higher (P <0.05), adverse reactions such as nausea, vomiting, diarrhea, creatinine, elevated transaminases and lower incidence of leukopenia (P <0.05). Conclusion: Combination of glycopyrrolate sodium and matrine injection can effectively improve the clinical efficacy of patients with esophageal cancer recurrence, prolong the survival time of patients with high safety.